Whether serputinib/serpatinib has been included in the medical insurance system

Selpercatinib has been launched in China and is widely used, but it has not yet been included in China's medical insurance directory. As a targeted therapy drug targeting RET gene mutations or fusions, seputinib is mainly used to treat RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer and other diseases. It has shown significant efficacy in clinical studies, especially in patients with advanced cancer who have failed to respond to conventional treatments.

However, although the efficacy of seputinib has been widely recognized and it has made important breakthroughs in the field of cancer treatment, it has not yet been included in the medical insurance system due to the high price of the drug and the cost of treatment is still a large financial burden for patients. At present, if patients want to use seputinib, they usually need to purchase it at their own expense, especially in the domestic market, where the original drug is relatively expensive.

However, with the popularization of this drug in clinical practice and further verification of its efficacy, it may be included in the medical insurance list in the future, especially for patients with diseases such as RET fusion-positive non-small cell lung cancer or RET-mutant medullary thyroid cancer, seputinib provides them with an effective treatment option. In fact, with the gradual improvement of my country's drug policy, many innovative drugs have gradually been included in medical insurance. Therefore, patients can expect that at some point in the future, seputinib may be included in medical insurance, reducing the financial burden on patients.

In general, although seputinib has not yet entered China's medical insurance system, as its clinical application gradually becomes more popular and its therapeutic effect continues to be verified, there may be more policy support in the future so that more patients can benefit from this innovative targeted therapy.

Reference:https://en.wikipedia.org/wiki/Selpercatinib